Pharmacoeconomic aspects of treatment of psoriasis with biological drugs
- Authors: Rudakova AV1, Kubanov AA2
-
Affiliations:
- Санкт-Петербургская химико-фармацевтическая академия
- ФГБУ «ГНЦДК» Минздравсоцразвития России
- Issue: Vol 88, No 2 (2012)
- Pages: 26-31
- Section: Articles
- URL: https://journals.rcsi.science/0042-4609/article/view/117109
- DOI: https://doi.org/10.25208/vdv663
- ID: 117109
Cite item
Full Text
Abstract
Psoriasis is an autoimmune skin disease substantially reducing the patients’ quality of life. Practical application of biologic drugs made it possible to achieve substantial progress in the psoriasis therapy. Goal of the article: comparative evaluation of the efficacy of etanercept, infliximab, adalimumab and ustekinumab costs in psoriatic patients. Methods. The cost efficacy was evaluated based on the results of randomized placebo-controlled studies. The analysis was conducted by the cost/efficiency method from the point of view of the health care system. Reduction in the severity of the disease by the PASI index vs. baseline was used as a criterion to evaluate the clinical efficacy. The evaluation was carried out for a course of therapy lasting for 52 weeks; the analysis took into consideration data on all patients (both responding and not responding to the treatment in 12 weeks) as well as patients failing to respond to the treatment in 12 weeks and withdrawing from the therapy. Costs and clinical efficacy were assessed for the time period equal to one year. The costs per one patient achieving PASI 75 were taken as the cost/efficacy coefficient. Results: treatment with adalimumab was shown to be characterized by a lower cost/efficacy coefficient vs. etanercept; infliximab or ustekinumab. Withdrawal in case of non-responding patients in 12 weeks reduces the therapy costs by 17%—40%. In this case, adalimumab proves to be more cost efficient. Conclusions. Treatment of psoriatic patients with adalimumab is expedient from the clinical and economic points of view since it is characterized by the minimum cost/efficacy ratio against the background of high clinical efficacy vs. etanercept; infliximab or ustekinumab.
Full Text
##article.viewOnOriginalSite##About the authors
A V Rudakova
Санкт-Петербургская химико-фармацевтическая академия
Email: rudakova_a@mail.ru
д.ф.н., проф. кафедры МФТВ
A A Kubanov
ФГБУ «ГНЦДК» Минздравсоцразвития Россиид.м.н., профессор, заместитель директора по научной работе Москва
References
- Smith C.H., Anstey A.V., Barker J.N.W.N., et al. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. BJD 2009; 161: 987—1019.
- Максимова Т., Лушкина Н. Российские пенсионеры и их зарубежные сверстники. Демоскоп weekly, № 435—436, 20.09—3.10.2010 (www.demoscope.ru).
- Сура М.В., Авксентьева М.В., Омельяновский В.В. и др. Клинико-экономический анализ применения устекинумаба (Стелара) у пациентов с тяжелой степенью псориаза. Медицинские технологии. 2011; 2: 23—28.
- Leonardi C.L., Powers J.L., Matheson R.T. et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014—22.
- Papp K.A., Tyring S., Lahfa M. et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. BJD 2005; 152: 1304—12.
- Tyring S., Gottlieb A.B., Papp K. et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29—35.
- Tyring S., Gordon K.B., Poulin Y. et al. Longterm safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719—26.
- Gottlieb A.B., Evans R., Li S. et al. Infliximab induction therapy for patients with severe plaquetype psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534—42.
- Reich K., Nestle F.O., Papp K. et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367—74.
- Menter A., Feldman S.R., Weinstein G.D. et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56: 31.
- Chaudhari U., Romano P., Mulcahy L.D. et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 2001; 357: 1842—7.
- Antoni C.E., Kavanaugh A., Kirkham B. et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005; 52: 1227—36.
- Gordon K.B., Langley R.G., Leonardi C. et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598—606.
- Menter A., Tyring S.K., Gordon K. et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial // J. Am. Acad. Dermatol. 2008; 58: 106—15.
- Saurat J.H., Stingl G., Dubertret L. et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 556—66.
- Mease P.J., Gladman D.D., Ritchlin C.T. et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 3279—89.
- Gladman D.D., Mease P.J., Ritchlin C.T. et al. Adalimumab for longterm treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007; 56: 476—88.
- Leonardi C.L., Kimball A.B., Papp K. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665—74.
- Papp K., Langley R.G., Lebwohl M. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675—84.
- Signorovitch J., Mulani P., Gupta S. et al. Cost per responder for biologic treatment of psoriasis: Matching-adjusted comparisons of adalimumab with etanercept, infliximab, and ustekinumab. 68th Annual Meeting of the American Academy of Dermatology (AAD); March 5—9, 2010; Miami, FL, USA. Abstract P203.
- Lazaro P., Blasco A., Ferrandiz C. et al. Efficiency (cost/efficacy) of biologic agents in the treatment of moderate to severe psoriasis. 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR); May 15—19, 2010; Atlanta, GA, USA. Abstract PSS9.
- Sizto S., Bansback N., Feldman S.R. et al. Economic evaluation of systemic therapies for moderate to severe psoriasis. BJD 2009; 160: 1264—1272.
- Приложения к Генеральному тарифному соглашению по тарифам на медицинскую помощь (медицинские услуги) и условиям оплаты медицинской помощи, оказываемой в рамках действующей Территориальной программы обязательного медицинского страхования граждан Российской Федерации в Санкт-Петербурге на 2011 г. (www.spboms.ru)
Supplementary files
